ED
Etzer Darout BMO Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
|
IVA
1
Inventiva
IVA
$779M
| $5.60 | $13 |
132%
upside
| Buy | 2 days ago |
|
2
Scholar Rock
SRRK
$3.12B
| $32.44 | $45 |
39%
upside
| Outperform | 28 days ago |
|
3
Terns Pharmaceuticals
TERN
$618M
| $7.06 | $15 |
112%
upside
| Outperform | 3 months ago |
|
4
Arvinas
ARVN
$559M
| $7.61 | $20 |
163%
upside
| Outperform | 5 months ago |
|
5
Protagonist Therapeutics
PTGX
$3.71B
| $59.60 | $72 |
21%
upside
| Outperform | 5 months ago |
|
6
BioNTech
BNTX
$24.9B
| $103.50 | $143 |
38%
upside
| Outperform | 5 months ago |
|
7
Merus
MRUS
$5.01B
| $66.23 | $96 |
45%
upside
| Outperform | 6 months ago |
|
8
Exelixis
EXEL
$10.1B
| $37.38 | $40 |
7%
upside
| Market Perform | 8 months ago |
|
9
Tourmaline Bio
TRML
$645M
| $25.10 | $50 |
99%
upside
| Outperform | 9 months ago |
|
10
Nurix Therapeutics
NRIX
$697M
| $9.12 | $35 |
284%
upside
| Outperform | 9 months ago |
|
11
Kymera Therapeutics
KYMR
$3.02B
| $42.20 | $55 |
30%
upside
| Market Perform | 9 months ago |
|
12
Nuvalent
NUVL
$5.74B
| $79.67 | $134 |
68%
upside
| Outperform | 9 months ago |
|
13
Xencor
XNCR
$597M
| $8.37 | $34 |
306%
upside
| Outperform | 10 months ago |
|
14
Genmab
GMAB
$16.8B
| $27.38 | $48 |
75%
upside
| Outperform | 10 months ago |
|
15
Novartis
NVS
$249B
| $128.42 | $120 |
7%
downside
| Market Perform | 10 months ago |
|
16
Y-mAbs Therapeutics
YMAB
$389M
| $8.57 | $25 |
192%
upside
| Outperform | 1 year ago |
|
17
CytomX Therapeutics
CTMX
$346M
| $2.10 | $3.59 |
71%
upside
| Market Perform | 1 year ago |
|
18
AstraZeneca
AZN
$254B
| $81.78 | $82 |
0%
upside
| Outperform | 1 year ago |
|
19
Foghorn Therapeutics
FHTX
$305M
| $5.39 | $19 |
253%
upside
| Outperform | 2 years ago |
|
20
Alnylam Pharmaceuticals
ALNY
$59.4B
| $453.54 | $170 |
63%
downside
| Buy | 3 years ago |
|
21
Akero Therapeutics
AKRO
$3.52B
| $44.03 | $54 |
23%
upside
| Buy | 4 years ago |
|
22
Mirum Pharmaceuticals
MIRM
$3.73B
| $74.18 | $38 |
49%
downside
| Buy | 5 years ago |
|